VLDL Cholesterol (very low density lipoprotein) is a lipoprotein subclass assembled in the liver from cholesterol and apolipoproteins. It is then converted in the bloodstream to low density lipoprotein (LDL). VLDL is prone to accelerate atherosclerosis, and is elevated in a number of diseases and metabolic states. It is composed mostly of cholesterol, with little protein. VLDL (and LDL) is often called “bad cholesterol” because it deposits cholesterol on your artery walls. VLDL transports endogenous triglycerides, phospholipids, cholesterol and cholesteryl esters. It functions as the body’s internal transport mechanism for lipids.
Why is this a problem?
Reducing low-density lipoprotein (LDL) cholesterol has long been the goal of medications and other cholesterol-lowering treatments, but researchers are finding that other lipoproteins appear to be involved in developing heart disease. These include some very low-density lipoproteins (VLDL) and intermediate-density lipoproteins (IDL) – which are types of non-HDL cholesterol. Studies have shown that the general category of “non-HDL” cholesterol, is a strong predictor of heart disease in people who have not yet developed signs of heart problems.
What can I do to lower my VLDL and non-HDL Cholesterol Levels?
LipidShield Plus™ has been clinically proven to lower cholesterol levels in a recent study. The study was an 8 week double blind placebo study involving 30 subjects. The results indicated statistical evidence of improving several aspects of blood lipids.
LipidShield Plus™ has been clinically proven to lower LDL cholesterol by up to 34%, VLDL by up to 76%, triglycerides by up to 76% and total cholesterol by up to 28%, while also helping to improve circulatory health.
Based on the lack of changes in standard clinical markers of hepato-renal function, the safety profile of LipidShield™ appears to be acceptable, at least during eight weeks of continuous use.